DUSP5 is Methylated in CIMP-high Colorectal Cancer but is Not a Major Regulator of Intestinal Cell Proliferation and Tumorigenesis

Overview

Journal Sci Rep

Specialty Science

Date 2018 Jan 31

PMID 29379130

Citations 10

Authors

Lars Togel

Rebecca Nightingale

Rui Wu

Anderly C Chueh

Sheren Al-Obaidi

Ian Luk

Mercedes Davalos-Salas

Fiona Chionh

Carmel Murone

Daniel D Buchanan

Zac Chatterton

Oliver M Sieber

Diego Arango

Niall C Tebbutt

David Williams

Amardeep S Dhillon

John M Mariadason

Affiliations

Soon will be listed here.

Abstract

The ERK signalling pathway regulates key cell fate decisions in the intestinal epithelium and is frequently dysregulated in colorectal cancers (CRCs). Variations in the dynamics of ERK activation can induce different biological outcomes and are regulated by multiple mechanisms, including activation of negative feedback loops involving transcriptional induction of dual-specificity phosphatases (DUSPs). We have found that the nuclear ERK-selective phosphatase DUSP5 is downregulated in colorectal tumours and cell lines, as previously observed in gastric and prostate cancer. The DUSP5 promoter is methylated in a subset of CRC cell lines and primary tumours, particularly those with a CpG island methylator phenotype (CIMP). However, this epigenetic change alone could not account for reduced DUSP5 expression in CRC cells. Functionally, DUSP5 depletion failed to alter ERK signalling or proliferation in CRC cell lines, and its transgenic overexpression in the mouse intestine had minimal impact on normal intestinal homeostasis or tumour development. Our results suggest that DUSP5 plays a limited role in regulating ERK signalling associated with the growth of colorectal tumours, but that methylation the DUSP5 gene promoter can serve as an additional means of identifying CIMP-high colorectal cancers.

Citing Articles

Revealing the Complete Bispecific Phosphatase Genes (DUSPs) across the Genome and Investigating the Expression Patterns of GH_A11G3500 Resistance against .

Deng Y, Deng X, Zhao J, Ning S, Gu A, Chen Q Int J Mol Sci. 2024; 25(8).

PMID: 38674085 PMC: 11050305. DOI: 10.3390/ijms25084500.

Targeting DUSP5 suppresses malignant phenotypes of BRAF-mutant thyroid cancer cells and improves their response to sorafenib.

Chen P, Wang J, Yao Y, Qu Y, Ji M, Hou P Endocrine. 2024; 85(3):1268-1277.

PMID: 38564084 DOI: 10.1007/s12020-024-03801-8.

Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues.

Wiltshire E, de Moura M, Pineyro D, Joshi R Hum Genomics. 2024; 18(1):24.

PMID: 38475971 PMC: 10935810. DOI: 10.1186/s40246-024-00592-x.

Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.

Kurahashi Y, Watanabe T, Yamamoto Y, Ureshino H, Kamachi K, Yoshida-Sakai N Blood Adv. 2022; 7(8):1545-1559.

PMID: 36516085 PMC: 10130614. DOI: 10.1182/bloodadvances.2022008362.

Suppression of mutant Kirsten-RAS (KRAS)-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6.

Kidger A, Saville M, Rushworth L, Davidson J, Stellzig J, Ono M Oncogene. 2022; 41(20):2811-2823.

PMID: 35418690 PMC: 9106580. DOI: 10.1038/s41388-022-02302-0.

References

Yan X, Liu L, Li H, Huang L, Yin M, Pan C . Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer. Am J Cancer Res. 2016; 6(10):2323-2333. PMC: 5088295. View

Rushworth L, Kidger A, Delavaine L, Stewart G, van Schelven S, Davidson J . Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression. Proc Natl Acad Sci U S A. 2014; 111(51):18267-72. PMC: 4280588. DOI: 10.1073/pnas.1420159112. View

Shaul Y, Seger R . The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2006; 1773(8):1213-26. DOI: 10.1016/j.bbamcr.2006.10.005. View

Jackstadt R, Sansom O . Mouse models of intestinal cancer. J Pathol. 2015; 238(2):141-51. PMC: 4832380. DOI: 10.1002/path.4645. View

Lake D, Correa S, Muller J . Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci. 2016; 73(23):4397-4413. PMC: 5075022. DOI: 10.1007/s00018-016-2297-8. View

Montero-Conde C, Ruiz-Llorente S, Dominguez J, Knauf J, Viale A, Sherman E . Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013; 3(5):520-33. PMC: 3651738. DOI: 10.1158/2159-8290.CD-12-0531. View

Kucharska A, Rushworth L, Staples C, Morrice N, Keyse S . Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK. Cell Signal. 2009; 21(12):1794-805. DOI: 10.1016/j.cellsig.2009.07.015. View

Mandl M, Slack D, Keyse S . Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol Cell Biol. 2005; 25(5):1830-45. PMC: 549372. DOI: 10.1128/MCB.25.5.1830-1845.2005. View

Camps M, Nichols A, Arkinstall S . Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000; 14(1):6-16. View

10.

Dhillon A, Hagan S, Rath O, Kolch W . MAP kinase signalling pathways in cancer. Oncogene. 2007; 26(22):3279-90. DOI: 10.1038/sj.onc.1210421. View

11.

Murphy L, Blenis J . MAPK signal specificity: the right place at the right time. Trends Biochem Sci. 2006; 31(5):268-75. DOI: 10.1016/j.tibs.2006.03.009. View

12.

Moarii M, Boeva V, Vert J, Reyal F . Changes in correlation between promoter methylation and gene expression in cancer. BMC Genomics. 2015; 16:873. PMC: 4625954. DOI: 10.1186/s12864-015-1994-2. View

13.

de Jong P, Taniguchi K, Harris A, Bertin S, Takahashi N, Duong J . ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation. Nat Commun. 2016; 7:11551. PMC: 4873670. DOI: 10.1038/ncomms11551. View

14.

Casalino L, De Cesare D, Verde P . Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol. 2003; 23(12):4401-15. PMC: 156136. DOI: 10.1128/MCB.23.12.4401-4415.2003. View

15.

Cagnol S, Rivard N . Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene. 2012; 32(5):564-76. DOI: 10.1038/onc.2012.88. View

16.

Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M . Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol. 2007; 27(11):3936-50. PMC: 1900028. DOI: 10.1128/MCB.01776-06. View

17.

Pratilas C, Taylor B, Ye Q, Viale A, Sander C, Solit D . (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009; 106(11):4519-24. PMC: 2649208. DOI: 10.1073/pnas.0900780106. View

18.

Piya S, Kim J, Bae J, Seol D, Moon A, Kim T . DUSP6 is a novel transcriptional target of p53 and regulates p53-mediated apoptosis by modulating expression levels of Bcl-2 family proteins. FEBS Lett. 2012; 586(23):4233-40. DOI: 10.1016/j.febslet.2012.10.031. View

19.

Madison B, Dunbar L, Qiao X, Braunstein K, Braunstein E, Gumucio D . Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem. 2002; 277(36):33275-83. DOI: 10.1074/jbc.M204935200. View

20.

Lao V, Grady W . Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(12):686-700. PMC: 3391545. DOI: 10.1038/nrgastro.2011.173. View